Latest news
Debiopharm applies for first europe marketing authorisation for Sanvar® in France
Debiopharm and Aurigene enter into an Agreement to identify and develop selective compounds for immuno-oncology targets
Moapar® 3-months approved for the lowering of testosterone to castrate serum levels for control of sexual drive in adult men
The Debiopharm Group and Sigma-Tau sign R&D and commercial agreement for Istaroxime in acute heart failure syndromes
The Debiopharm Group to initiate confirmatory phase III trial for Sanvar® in esophageal variceal bleeding
Debiopharm and TcLand sign R&D and exclusive license option for the development of sc28AT autoimmune diseases and transplantation
Debiopharm et la Haute Ecole Valaisanne collaborent pour développer les médicaments de demain
Debiopharm presents phase I monthly implant and phase II daily oral results of ZT-1 for Alzheimer´s disease